Full Press Release Details
SOUTH PLAINFIELD, N.J. , June 13, 2016 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT ) today announced the appointment of Dawn Svoronos to the company's Board of Directors. Ms. Svoronos most recently served as President of Merck's Europe / Canada region from 2009 to 2011 and as President of Merck in Canada from 2006 to 2009.
"We are thrilled to have Dawn joining our Board of Directors," said Stuart W. Peltz , Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Dawn brings extensive commercial and leadership experience from her impressive contributions at Merck. Dawn's global commercialization expertise makes her a valuable advisor as we continue expanding access to Translarna worldwide."
Ms. Svoronos has more than 30 years of experience in the pharmaceutical industry, including her tenure as President of Merck & Company's Europe / Canada region. Previously held positions with Merck include President of Merck in Canada , Vice President of Asia Pacific and Vice President of Global Marketing for the Arthritis, Analgesics and Osteoporosis franchise. Ms. Svoronos is currently Chair of the Board of Directors for Theratechnolgies Inc., a specialty pharmaceutical company that trades on the Toronto Stock Exchange. Ms. Svoronos also serves on the board of Medivation Inc., a Nasdaq-listed biopharmaceutical company in San Francisco and is a member of the board of Agnovos Healthcare Company, a privately held organization in New York .
About PTC Therapeutics PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. Post-transcriptional control processes are the regulatory events that occur in cells during and after a messenger RNA, or mRNA, molecule is copied from DNA through the transcription process. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders and oncology. PTC has discovered all of its compounds currently under development using its proprietary technologies. PTC plans to continue to develop these compounds both on its own and through selective collaboration arrangements with leading pharmaceutical and biotechnology companies. For more information on the company, please visit our website www.ptcbio.com .
For More Information:
Investors: Jane Baj +1 (908) 912-9167 [email protected]
Media: Justine O'Malley +1 (908) 912-9551 [email protected]
Forward Looking Statements: All statements, other than those of historical fact, contained in this press release, are forward-looking statements, including statements regarding the future expectations, plans and prospects for PTC; PTC's ability to maintain its current marketing authorizations, including in the European Economic Area (EEA), or obtain and maintain additional marketing authorizations; the timing and scope of PTC's commercial and early access program launches; the potential for PTC to continue to commercialize Translarna for nonsense mutation Duchenne muscular dystrophy (nmDMD) in territories where PTC is or may be authorized to market Translarna, including the price of Translarna in such territories; the clinical utility and potential advantages of Translarna; the rate and degree of market acceptance of Translarna; PTC's estimates regarding the potential market opportunity for Translarna; the timing, results and conduct of PTC's clinical trials and studies of Translarna; PTC's strategy, future operations, future financial position, future revenues or projected costs; and the objectives of management. Other forward-looking statements may be identified by the words "will," "work towards," "anticipate," "believe," "estimate," "expect," "intend," "may," "predict," "project," "plan," "potential," "would," "could," "should," "continue," and similar expressions.
As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that Translarna will receive full regulatory approval in any territory or maintain its current marketing authorization in the EEA, or prove to be commercially successful in general, or specifically with respect to the treatment of nmDMD.
The forward-looking statements contained herein represent PTC's views only as of the date of this press release and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this press release except as required by law.
SOURCE PTC Therapeutics, Inc.